A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

Until recently, the approved first-line treatment for metastatic RCC (mRCC) consisted of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor receptors (VEGFR) monotherapy. The landscape of first-line treatment has been transformed in the last few years with the advent o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiako Meyo, Manuela, Chen, Jeanne, Goldwasser, Francois, Hirsch, Laure, Huillard, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275425/
https://www.ncbi.nlm.nih.gov/pubmed/35837579
http://dx.doi.org/10.2147/TCRM.S263832
_version_ 1784745481491972096
author Tiako Meyo, Manuela
Chen, Jeanne
Goldwasser, Francois
Hirsch, Laure
Huillard, Olivier
author_facet Tiako Meyo, Manuela
Chen, Jeanne
Goldwasser, Francois
Hirsch, Laure
Huillard, Olivier
author_sort Tiako Meyo, Manuela
collection PubMed
description Until recently, the approved first-line treatment for metastatic RCC (mRCC) consisted of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor receptors (VEGFR) monotherapy. The landscape of first-line treatment has been transformed in the last few years with the advent of immune checkpoint inhibitors (ICI) or VEGFR TKI plus ICI combinations. This article focuses on the profile of one of these ICI plus VEGFR TKI combination, avelumab plus axitinib. We detail the characteristics of each drug separately, and then we explore the rationale for their association, its efficacy and the resulting toxicity. Finally, we examine the factors associated with avelumab plus axitinib outcomes, and their impact on therapeutic strategy.
format Online
Article
Text
id pubmed-9275425
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92754252022-07-13 A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma Tiako Meyo, Manuela Chen, Jeanne Goldwasser, Francois Hirsch, Laure Huillard, Olivier Ther Clin Risk Manag Review Until recently, the approved first-line treatment for metastatic RCC (mRCC) consisted of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor receptors (VEGFR) monotherapy. The landscape of first-line treatment has been transformed in the last few years with the advent of immune checkpoint inhibitors (ICI) or VEGFR TKI plus ICI combinations. This article focuses on the profile of one of these ICI plus VEGFR TKI combination, avelumab plus axitinib. We detail the characteristics of each drug separately, and then we explore the rationale for their association, its efficacy and the resulting toxicity. Finally, we examine the factors associated with avelumab plus axitinib outcomes, and their impact on therapeutic strategy. Dove 2022-07-08 /pmc/articles/PMC9275425/ /pubmed/35837579 http://dx.doi.org/10.2147/TCRM.S263832 Text en © 2022 Tiako Meyo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Tiako Meyo, Manuela
Chen, Jeanne
Goldwasser, Francois
Hirsch, Laure
Huillard, Olivier
A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
title A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
title_full A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
title_fullStr A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
title_full_unstemmed A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
title_short A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
title_sort profile of avelumab plus axitinib in the treatment of renal cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275425/
https://www.ncbi.nlm.nih.gov/pubmed/35837579
http://dx.doi.org/10.2147/TCRM.S263832
work_keys_str_mv AT tiakomeyomanuela aprofileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT chenjeanne aprofileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT goldwasserfrancois aprofileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT hirschlaure aprofileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT huillardolivier aprofileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT tiakomeyomanuela profileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT chenjeanne profileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT goldwasserfrancois profileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT hirschlaure profileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma
AT huillardolivier profileofavelumabplusaxitinibinthetreatmentofrenalcellcarcinoma

Ejemplares similares